Macau University of Science and Technology

Hong Kong Baptist University

Everite Consultants Ltd.

Liang Liu

Kam Wai Wong

Yuen Kwan Law

Xiao Jun Yao

Jingrong Wang

Hua Zhou

Xiao-Jun Yao

Lai Han Elaine Leung

Lai Han Leung

Zhihong Jiang

Elaine Lai-Han Leung

Ying Li

Zhi-Hong Jiang

Lian-Xiang Luo

Lian Xiang Luo

Ting Li

Lai-Han Elaine Leung

Xing-Xing Fan

Ying Xie

Jia Hui Xu

Qian Qian Wang

Jing-Rong Wang

Vincent Kam-Wai Wong

Thomas Efferth

Weina Gao

Xing Xing Fan

Chun Xie

Leefong Yau

Xi Chen

Wen-zhe Ma

Sen-ling Feng

Zhong-wen Yuan

Hao Huang

Tiantian Tong

Qiong Meng

Min Li

Hang Dong

Li-Ping Bai

Guo-Yuan Zhu

Liping Bai

Pei Luo

Fenggen Yan

An Guo Wu

Jing Rong Wang

Xin Liu

Zhongqiu Liu

Jing Fu

Cong Ling Qiu

Onat Kadioglu

Xia Li

An Gao Wu

Guoyuan Zhu

Zeng Wu

Fen Yang

Hu Dan Pan

David Ward

Su-Wei Xu

Sami Hamdoun

Xiao-jun Yao

Run-Ze Li

Wai In Chan

Ji Yang

Zhi Hong Jiang

Lai-Han Leung

Quanbing Han

Zebo Jiang

Yihan Zuo

Yan Ling Zhou

Ruiqi Yue

Wen-Luan Hsiao

The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.

Use of glycan as biomarkers for autoimmune diseases

A method of identifying a gene associated with a disease or pathological condition of the disease includes: a) obtaining a first group of exome sequences from a first population suffering from the disease or pathological condition and a second group of exome sequences from a second population not having the disease or pathological condition; b) identifying one or more variants in the first group by comparing it with the second group, and optionally with a public database, to generate a first set of variant data; c) applying a variant quality score calibration tool with a truth sensitivity threshold to remove false-positive variants having a sensitivity lower than the threshold and background variants from the first set of variant data so as to obtain a second set of variant data; d) removing synonymous variants from the second set of variant data to obtain a third set of variant data; and e) identifying one or more deleterious variants from the third set of variant data using a gene burden analysis, optionally generating a fourth set of variant data.

Method of identifying a gene associated with a disease or pathological condition of the disease

One embodiment is a method of treating cancer. The method includes administering a therapeutically effective amount of a compound to a patient. The compound is represented by Formula I: 

Methods of treating cancer

A method for treating a subject suffering from refractory rheumatoid arthritis includes the step of administering an effective amount of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof to the subject. Also is a method for inducing autophagy in a synovial fibroblast, and a method of inducing calcium mobilization in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA) in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

Method of treating refractory rheumatoid arthritis associated with p53 mutation

A method for treating a subject suffering from a neurodegenerative disease includes administering at least one triterpenoid which can be obtained from. A method for treating a subject suffering from a neurodegenerative disease includes administering an effective amount of aextract which comprises the triterpenoid. The neurodegenerative disease is preferably but not exclusively Parkinson's disease or Huntington's disease. Methods for extracting the triterpenoid fromand a method for inducing autophagy in cells by contacting them with the triterpenoid are also provided. The triterpenoid allows an exceptional induction of autophagy, in particular a significant reduction of the protein level of mutant huntingtin, a significant reduction of the protein level of A53T &#x3b1;-synuclein, a significant inhibition of the oligomerization of &#x3b1;-synuclein and a significant inhibition of the inclusion formation of huntingtin via the AMPK-mTOR dependent autophagy inducing pathway.

Triterpenoid obtainable from hedera helix for treatment of neurodegenerative diseases

A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.

Treatment of subjects with multidrug-resistant cancer

One example embodiment relates to a method of increasing bioavailability of silybin in a person. The method includes providing silybin and a flavonoid to the person, wherein the flavonoid is tangeretin or baicalein. Another example embodiment relates to a method of treating chronic liver disease in a person by administering silybin and a flavonoid to the person to treat the chronic liver disease.

Method of increasing the bioavailability of silybin

Methods of treating a subject suffering from an ischemic condition and of preventing an ischemia-reperfusion injury in a subject suffering from an ischemic condition, particularly, but not exclusively ischemic heart disease and the subject is in particular a human, includes administering an effective amount of a carbohydrate composition extracted fromto the subject. The carbohydrate composition of the present invention extracted fromshows exceptional cardio-protective effect and, thus, provides a highly advantageous and highly promising treatment option for treatment of ischemic conditions and prevention of ischemia-reperfusion injury. The present invention further provides a method of protecting cells against hypoxia and reoxygenation induced cell death. Still further, the present invention provides a carbohydrate composition extracted fromand a pharmaceutical formulation comprising it.

[object Object]

One example embodiment is a lignanamide that includes a benzo-angular triquinane skeleton. The lignanamide is represented by formula (I) and any derivative of the formula (I), in which R is represented by &#x2014;OH or &#x2014;OCH3. Another example embodiment relates to a method of treating neurodegenerative disease by administering the lignanamide of the formula (I) to a person in need thereof. 

Lignanamides and a method of treating neurodegenerative diseases by using the same

A compound for treating a disease, in particular cancer like non-small cell lung cancer, exceptionally inhibits activity of oncogenic ALK kinase. Compositions, particularly pharmaceutical compositions, are provided comprising this compound. Methods for targeting cancer cells harboring an abnormality in the ALK gene are also The compound for treating a disease has certain structural elements, namely a tricyclic, more specifically heterocyclic, backbone as the core part of the compound at least one highly electronegative atom in form of a tertiary amine attached to the backbone via an at most 6-membered linking group with a terminal highly electronegative atom in form of a nitrogen as secondary amine, and a further hydrophobic moiety fused to the backbone. The structural components allow for an advantageous interaction with the ALK kinase domain. The compound therefor represents a highly promising treatment option for patients in particular those bearing ALK-dependent non-small cell lung cancer.

ALK Kinase Inhibitor and its use

Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant. Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit including a prenylated isoflavone and a chemotherapeutic compound is provided.

Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer

The administration of a compound advantageously efficacious as ROS1 inhibitor and its effect on subjects with cancer includes administering a compound having certain structural components such as a quinoline moiety in the backbone and at least one tertiary amine containing moiety in a side chain as well as heteroatoms, in particular oxygen atoms, present in the backbone and the side chain for treating a subject suffering from a disease such as cancer. The presence of such structural components allows for an advantageous interaction with the ROS1 kinase domain, in particular with the hinge region. The administered compounds represent a highly promising opportunity in particular for patients bearing ROS1-dependent cancer. A method for targeting tumor cells harboring an abnormality in ROS1 gene includes contacting a cell with compounds of the present invention as well as pharmaceutical compositions comprising such compounds.

ROS1 inhibitor and its use

Growing community of inventors

Macau, China

Liang Liu